Estimation of D-Dimer Level among Sudanese Patients with COVID-19 Infection-Khartoum State 2022
Abstract
Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causing coronavirusdisease 2019 (COVID-19) has rapidly evolved from an epidemic outbreak in Wuhan, China into a pandemic infecting more than one million individuals all over the world, where as billions of citizens are affected by measures of social distancing and the socioeconomic impact of the pandemic
Material and methods: This was case control study, conduct at COVID-19 quarantine hospitals in Khartoum state during the period from May to July 2022, for the measurement of D-dimer level among Sudanese covid 19 patients. One hundred participants were selected as cases and apparently fifty participants were selected as control group. 2.8 ml of venous blood samples were collected in Tri Sodium Citrate anticoagulant The D-dimer was performed using B50protein analyzer .
Results: When compared the D-dimer results between case and control there was highly significant difference with p.value 0.000. In addition the D-dimer in cases compared with the other study variables which revealed; significant differences with the chronic disease and the severity of the disease, in significant differences with the age, gender and smoking status.
Conclusion: This study concluded that D-dimer was significantly increase in COVID-19 patients, and it had significant differences with the chronic disease and the severity of the disease, insignificant differences with the age, gender and smoking status.
Keywords: COVID-19, SARS-CoV-2, D-dimer, chronic disease and B50protein analyzer
Keywords:
COVID-19, SARS-CoV-2, D-dimer, chronic disease, B50protein analyzerDOI
https://doi.org/10.22270/jddt.v12i5.5626References
- Driggin E, Madhavan MV, Bikdeli B, et al. Cardiovascular Considerations forPatients, Health Care Workers, and Health Systems During the Coronavirus Disease 2019(COVID-19) Pandemic. J Am CollCardiol2020 Mar 18. https://doi.org/10.1016/j.jacc.2020.03.031
- Bangash MN, Patel J, Parekh D. COVID-19 and the liver: little cause for concern.Lancet GastroenterolHepatol 2020; 20. https://doi.org/10.1016/S2468-1253(20)30084-4
- Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine stormsyndromes and immunosuppression. Lancet 2020 Mar 28; 395(10229):1033-1034. https://doi.org/10.1016/S0140-6736(20)30628-0
- Fei Z et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet (London, England) 2020; 395(10229):1054-62 https://doi.org/10.1016/S0140-6736(20)30566-3
- Wright FL et al (2020). Fibrinolysis shutdown correlates to thromboembolic events in severe COVID-19 infection. J Am CollSurg [cited 14 Jun 2020]. Available from: https://pubmed.ncbi.nlm.nih. gov/32422349/ https://doi.org/10.1016/j.jamcollsurg.2020.05.007
- Schmitt FCF, Manolov V, Morgenstern J, Fleming T, Heitmeier S, Uhle F et al. Acute fbrinolysis shutdown occurs early in septic shock and is associated with increased morbidity and mortality: results of an observational pilot study. Ann Intensive Care 2019; 9(1):19 https://doi.org/10.1186/s13613-019-0499-6
- Stettler GR, Moore EE, Moore HB, Nunns GR, Silliman CC, Banerjee A et al. Redefningpostinjuryfbrinolysis phenotypes using two viscoelastic assays. J Trauma Acute Care Surg 2019; 86(4):679-685. https://doi.org/10.1097/TA.0000000000002165
- Kuiper GJAJM, Kleinegris MCF, van Oerle R, Spronk HMH, Lancé MD, ten Cate H et al. Validation of a modified thromboelastometry approach to detect changes in fbrinolytic activity. Thromb 2016; 14:1 https://doi.org/10.1186/s12959-016-0076-2
- Zhu, F. C. et al. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet 2020; 396, 479-488. https://doi.org/10.1016/S0140-6736(20)31605-6
- Bikdeli B, Madhavan MV, Jimenez D, et al. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up: JACC state-of-the-art review. J Am CollCardiol. 2020; 75(23):2950-2973. https://doi.org/10.1016/j.jacc.2020.04.031
- Araya S, Mamo MA, Tsegay YG, Atlaw A, Aytenew A, Hordofa A, et al. Blood coagulation parameter abnormalities in hospitalized patients with confirmed COVID-19 in Ethiopia. PLoS ONE 2021; 16(6):e0252939. https://doi.org/10.1371/journal.pone.0252939
- Babak Sayad and Zohreh Rahimi. Blood coagulation parameters in patients with severe COVID-19 fromKermanshah Province, Islamic Republic of Iran. EMHJ 2020; 26(9):999-1004 https://doi.org/10.26719/emhj.20.105
- C. Ibañez, et al. High D dimers and low global fbrinolysis coexist in COVID19 patients: what is going on in there? Journal of Thrombosis and Thrombolysis 2020 https://doi.org/10.1007/s11239-020-02226-0
- Thiago Domingos Corrêa, et al. Coagulation profile of COVID-19 patients admitted to the ICU: An exploratory study. PLos One 2020 Dec 15; 15(12):e0243604. https://doi.org/10.1371/journal.pone.0243604
- Franklin L Wright, et al. Fibrinolysis Shutdown Correlation with Thromboembolic Events in Severe COVID-19 Infection. J Am Coll Surg 2020; 231:193-204. https://doi.org/10.1016/j.jamcollsurg.2020.05.007
- Islam Eljilany and Abdel-Naser Elzouki. D-Dimer, Fibrinogen, and IL-6 in COVID-19 Patients with Suspected Venous Thromboembolism: A Narrative Review. Vascular Health and Risk Management 2020; 16:455-462 https://doi.org/10.2147/VHRM.S280962
- Lili Luo, et al, Early coagulation tests predict risk stratification and prognosis of COVID-19. Aging 2020; 12(16):15918-15937 https://doi.org/10.18632/aging.103581
- Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020; 28. https://doi.org/10.1056/NEJMoa2002032
- Evangelos Terpos, et al. Hematological findings and complications of COVID-19. Am J Hematol. 2020; 1-14
- Rongrong Ding, et al. Identification of parameters in routine blood and coagulation tests related to the severity of COVID-19. International Journal of Medical Sciences 2021; 18(5):1207-1215. https://doi.org/10.7150/ijms.47494
Published
Abstract Display: 461 
PDF Downloads: 468 PDF Downloads: 20 How to Cite
Issue
Section
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
.